|
Match
|
Document |
Document Title |
|
|
US20160046636 |
TYPE II RAF KINASE INHIBITORS
The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions. |
|
|
US20160024087 |
MLK INHIBITORS AND METHODS OF USE
Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods... |
|
|
US20150152103 |
AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the... |
|
|
US20150118186 |
PYRAZOLE DERIVATIVES AS JAK INHIBITORS
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy... |
|
|
US20150065504 |
ANTIVIRAL COMPOUNDS
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein... |
|
|
US20140378505 |
SNS-595 AND METHODS OF USING THE SAME
The present invention relates to SNS-595 and of treating cancer using the same. |
|
|
US20140303164 |
THERAPEUTIC COMPOUNDS
Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I,... |
|
|
US20140288116 |
Classification and Actionability Indices for Lung Cancer
The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with lung cancer. The compositions, kits, and methods... |
|
|
US20140038948 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. |
|
|
US20130245025 |
Compounds that modulate intracellular calcium
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of... |
|
|
US20130231344 |
COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of... |
|
|
US20110301127 |
METHODS OF REDUCING MICROBIAL RESISTANCE TO DRUGS
The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly... |
|
|
US20100190731 |
METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS
The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs... |
|
|
US20090297619 |
NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20080248123 |
Nanoparticulate anticonvulsant and immunosuppressive compositions
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20080032960 |
PI3 kinase antagonists
The present invention provides novel PI3-Kinase antagonists and methods of use thereof. |
|
|
US20070225217 |
Methods, compositions, and kits for the treatment of medical conditions
The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal... |
|
|
US20060063795 |
SNS-595 and methods of using the same
The present invention relates to SNS-595 and methods of treating cancer using the same. |
|
|
US20060025437 |
SNS-595 and methods of using the same
The present invention relates to SNS-595 and methods of treating cancer using the same. |
|
|
US20170066765 |
CRYSTALLINE BROMODOMAIN INHIBITORS
N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-
pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for... |
|
|
US20170065517 |
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises... |
|
|
US20160265065 |
Classification and Actionability Indices for Lung Cancer
The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with lung cancer. The compositions, kits, and methods... |
|
|
US20160237085 |
CRYSTALLINE BROMODOMAIN INHIBITORS
N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-
pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for... |
|
|
US20160060262 |
Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof
The invention provides novel compounds having the general formula: wherein X1 is N or N+O−, and one of X2, X3 and X4 is N or N+—O− and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B... |
|
|
US20150266899 |
ANTI-FIBROTIC PYRIDINONES
Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders. |
|
|
US20150125452 |
COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological... |
|
|
US20150118301 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
|
US20150118300 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
|
US20130345218 |
INHIBITORS OF INFLUENZA VIRUSES REPLICATION
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating... |
|
|
US20130245037 |
Stabilization of Hypoxia Inducible Factor (HIF) Alpha
The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating... |
|
|
US20130172375 |
PHARMACEUTICAL COMPOSITION
The present invention relates to a pharmaceutical composition comprising a solid dispersion of a drug. In the composition, the drug is in substantially amorphous form. |
|
|
US20130078252 |
COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological... |
|
|
US20120101093 |
SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site... |
|
|
US20120040950 |
ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and... |
|
|
US20110281850 |
INTRACELLULAR KINASE INHIBITORS
Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs. |
|
|
US20110092447 |
USING INHIBITORS OF HISTONE DEACETYLASES FOR THE SUPPRESSION THERAPY OF INHERITED DISEASE PREDISPOSING CONDITIONS
Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as... |
|
|
US20100291004 |
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises... |
|
|
US20100143384 |
NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole... |
|
|
US20100137326 |
NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole... |
|
|
US20090258070 |
Topical LFA-1 antagonists for use in localized treatment of immune related disorders
This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are... |
|
|
US20090258069 |
Delivery of LFA-1 antagonists to the gastrointestinal system
The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1... |
|
|
US20090181971 |
Inhibitors of Histone Deacetylase
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides... |
|
|
US20090118233 |
Heterocyclic compounds having inhibitory activity against HIV integrase
A heterocyclic compound of the formula (I): wherein B1 is —C(R2)═ or —N═; R1′ is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted... |
|
|
US20090022670 |
NOVEL COMPOUNDS
Disclosed are imidazo[1,2-a]pyridin-2-ylmethyl substituted piperidine derivatives of formula (I) and their use as pharmaceuticals. |
|
|
US20080021026 |
BENZOTHIOPHENE INHIBITORS OF RHO KINASE
The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease. |
|
|
US20170020851 |
TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). |
|
|
US20170014390 |
TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). |
|
|
US20150320727 |
HETEROCYCLIC COMPOUNDS AND USES THEREOF
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and... |
|
|
US20150290177 |
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises... |
|
|
US20150140082 |
COMPOSITIONS AND METHODS FOR TREATMENT
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the... |